LLY Eli Lilly and Company March 16, 2026 RBC Maintains Outperform

NodeGuardian · 2026-03-17T04:26:49+00:00

RBC Capital maintains an Outperform rating for Eli Lilly due to the anticipated success of its drug Orfo, predicting market share gains and strong performance over peers. Meyka AI also supports this optimistic outlook with an 'A' grade but cautions investors on risks.

NodeGuardian

2026-03-17 04:26:49

Abstract generation in progress

RBC Capital has reaffirmed its Outperform rating for Eli Lilly and Company (LLY) on March 16, 2026, driven primarily by the anticipated approval and launch of its drug, Orfo. The analyst firm highlighted Orfo’s potential for market share gains and pricing power as a key upside and expects LLY to outperform its peers over the next year. Meyka AI also assigns LLY an ‘A’ grade, supporting the positive outlook while advising investors to consider valuation, launch execution, and competitive risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.